Morningstar Acciones

Smith & Nephew PLC SN. StarRatingValueLabel_5Mr. Lee Davidson, Head of Quantitative Research

Latest Morningstar Commentary
FechaAuthor Titular

Latest Company News

FechaTimeSourceTitularTipo de activo
Previous Stories...
08/04/202422:01DJNM*DJ Smith+Nephew Signs Exclusive Distribution Agreement to Provide Unique NAVBIT SPRINT Solution in Australia
08/04/202422:00DJNMSmith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT(TM) solution in Australia
08/04/202422:00DJNMPress Release: Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT(TM) solution in Australia
04/04/202415:13DJNMPress Release: Smith+Nephew's PICO(TM) Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
04/04/202415:13DJNMSmith+Nephew's PICO(TM) Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
04/04/202415:13DJNMPress Release: Smith+Nephew's PICO(TM) Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
04/04/202415:13DJNMPress Release: Smith+Nephew's PICO(TM) Single Use -2-
02/04/202412:43LSETotal Voting RightsTVR
02/04/202412:19LSEDirector/PDMR ShareholdingDSH
01/04/202412:00DJNMPress Release: Smith+Nephew introduces the RENASYS(TM) EDGE Negative Pressure Wound Therapy System -- an exciting new option in home-based care for patients living with chronic wounds
01/04/202412:00DJNMPress Release: Smith+Nephew introduces the RENASYS(TM) EDGE Negative Pressure Wound Therapy System -- an exciting new option in home-based care for patients living with chronic wounds
01/04/202412:00DJNMSmith+Nephew introduces the RENASYS(TM) EDGE Negative Pressure Wound Therapy System -- an exciting new option in home-based care for patients living with chronic wounds
28/03/202407:08DJNMDJ Smith & Nephew Names John Rogers CFO as Anne-Francoise Nesmes Exits
28/03/202407:02DJNM*DJ Smith & Nephew: Rogers Succeeds Anne-Francoise Nesmes
28/03/202407:01DJNM*DJ Smith & Nephew: John Rogers Appointed CFO
28/03/202407:00LSEDirectorate ChangeBOA
25/03/202412:00DJNMSmith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
25/03/202412:00DJNMPress Release: Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
25/03/202412:00DJNMPress Release: Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
14/03/202407:05DJNM*DJ Smith & Nephew: Funds to Repay Revolving Credit Facility Balance
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. Reservados todos los derechos.

Términos de uso        Política Privacidad        Cookie Settings        Aviso Legal